MARATTO

article · BMC Medicine

Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria – a proposed model-derived age-based regimen for sub-Saharan Africa

201847 citationsOpen accessUniversité de Kinshasa (UNIKIN)

In plain language

The abstract on record is too brief for a reliable plain-language summary, so none has been generated.

Abstract

We plan to test the safety of this age-based dosing regimen in a large randomised placebo-controlled trial (ISRCTN11594437) of uncomplicated falciparum malaria in G6PDd African children aged 0.5 - 11 years. If the regimen is safe and demonstrates adequate pharmacokinetics, it should be used to support malaria elimination.

Research topics

  • Malaria Research and Control
  • Hemoglobinopathies and Related Disorders
  • Pharmacological Effects and Toxicity Studies

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher siteRecord on OpenAlex

DOI: 10.1186/s12916-017-0990-6

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

Sign in to join the discussion

New to MARATTO™? Create a free account.